Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05095792
Other study ID # EBIQ-101
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 9, 2021
Est. completion date October 21, 2022

Study information

Verified date November 2022
Source Entheon Biomedical Corp.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This observational study will allow data to be collected to demonstrate changes in brain activity following administration of standard of care (SOC) Ketamine. By comparing genetic markers across participants, data on impact of genetic markers and response to Ketamine will also be analysed. This data will contribute to the design of future studies utilizing Ketamine for various psychiatric disorders. This study will focus on treatment-resistant Major Depressive Disorder (MDD).


Description:

This is an Open Label Observational Study with the primary objective to assess brain activity in patients prior to, during and after Ketamine treatment and to assess genetic markers prior to Ketamine treatment. This is a non-interventional study that will observe the Electroencephalogram (EEG) pattern of participants who, per standard of care, are treated with intramuscular Ketamine. The administration of the Ketamine during this study is not considered investigational. The experimental intervention, measurements via EEG, will be offered to patients of the study site presenting for intramuscular (IM) ketamine treatment per the site's established and evidence-based protocol as part of their regular clinical care. Participants in this study have already been determined to have a medically appropriate indication for IM Ketamine treatment, independent of enrollment in this study. Given the requirement, per study protocol, to wear an EEG headset and complete study measures, participants will be compensated by having treatment costs paid by the study sponsor. There will be 36 participants enrolled at one study site.


Recruitment information / eligibility

Status Completed
Enrollment 1
Est. completion date October 21, 2022
Est. primary completion date October 21, 2022
Accepts healthy volunteers No
Gender All
Age group 21 Years to 60 Years
Eligibility Inclusion Criteria: 1. Primary Diagnostic and Statistical Manuel of Mental Disorders 5 (DSM-V) diagnosis of treatment-resistant Major Depressive Disorder (may have secondary diagnoses of general anxiety, substance disorder) - Non-responders to at least 2 previous anti-depressant medications prescribed by a physician in the past five years - Score of =20 on Montgomery-Asberg Depression Rating Scale (MADRS) (i.e., moderate to severe depression) 2. All genders aged 21 to 60 years of age 3. Prescribed Ketamine or currently being treated with Ketamine for treatment-resistant Major Depressive Disorder 4. Willing to wear an Electroencephalogram (EEG) headset and an eye mask 5. Willing to listen to ambient sound 6. Willing to have a genetic cheek swab Exclusion Criteria: 1. Pregnancy 2. Traumatic Brain Injury within past 3 months 3. Body weight < 50 kg or > 120 kg 4. Coronary heart disease 5. Uncontrolled hypertension as defined in the American College of Cardiology/American Heart Association (ACC/AHA) Hypertension Guidelines 6. Previous contact with Ketamine (therapeutically or recreationally) outside of treatment at the study site 7. Primary psychotic disorder (e.g., schizophrenia, schizoaffective disorder) 8. Bipolar disorder with current manic, hypomanic or mixed state 9. Post-traumatic stress disorder 10. Obsessive-compulsive disorder 11. Primary substance-use disorder 12. Alcohol consumption 24 hours prior and 48 hours subsequent to treatment 13. Currently using any of the following medications: - Benzodiazepines for 6 hours prior to treatment and 2 hours after treatment - Lamotrigine for 6 hours prior to treatment - Amphetamine-based stimulants for 6 hours prior to treatment - Monoamine Oxidase Inhibitors (MAO-Is) may be taken but blood pressure must be monitored

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Observational - no intervention
This is an observational study with no intervention.

Locations

Country Name City State
United States Heading Health Austin Texas

Sponsors (1)

Lead Sponsor Collaborator
Entheon Biomedical Corp.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Inter and intra patient variability in neurological activity. Observation of the the inter and intra patient variability in neurological activity. Up to 74 days
Secondary Genetic markers on neurological phenotypes Correlation of neurological phenotypes with genetic markers Baseline
Secondary CADSS-6 correlation with neurological phenotypes Correlation of neurological phenotypes of Clinician Administered Dissociative Symptom Scale (CADSS-6). Up to 67 days
Secondary QIDS SR-16 correlation with neurological phenotypes Correlation of neurological phenotypes of depressed patients with Quick Inventory of Depressive Symptomatology (QIDS SR-16) Up to 67 days
Secondary PMQ-SF correlation with neurological phenotypes Correlation of neurological phenotypes Psychedelic Music Questionnaire Short Form (PMQ-SF) Up to 67 days
See also
  Status Clinical Trial Phase
Completed NCT02497287 - A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression Phase 3
Recruiting NCT03653858 - Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression N/A
Recruiting NCT02462551 - Focal Electrically Administered Seizure Therapy for the Treatment of Depression N/A
Recruiting NCT01868802 - Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population Phase 2
Recruiting NCT05377177 - Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI N/A
Recruiting NCT06372834 - Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients N/A
Active, not recruiting NCT03701724 - Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression N/A
Recruiting NCT05800860 - A Trial of GH001 in Patients With Treatment-resistant Depression Phase 2
Not yet recruiting NCT06404320 - Physical Activity Program for TRD N/A
Completed NCT01945047 - Action of Ketamine in Treatment-Resistant Depression Phase 2/Phase 3
Recruiting NCT05045378 - Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression Phase 4
Completed NCT05454410 - Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD) Phase 2
Recruiting NCT05422417 - Dorsomedial Prefrontal Neuromodulation in Treatment-resistant Depression N/A
Recruiting NCT05842291 - pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression N/A
Recruiting NCT04821271 - Antidepressant Effects of TS-161 in Treatment-Resistant Depression Phase 2
Active, not recruiting NCT04670081 - Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression Phase 2
Terminated NCT01598324 - Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder N/A
Recruiting NCT05710237 - Does Psilocybin Require Psychedelic Effects to Treat Depression? Phase 2
Completed NCT03329391 - Psychosocial Characteristics and Non-pharmacological Intervention of Patients With Treatment-resistant Depression N/A
Not yet recruiting NCT05661383 - Olfactory and Brain Stimulations in Treatment-resistant Depression N/A